November 10, 2022

GLP-1 Receptor Agonists and the Risk of Thyroid Cancer

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

In the current study we found increased risk of all thyroid cancer and medullary thyroid cancer with use of GLP-1 RA, in particular after 1-3 years of treatment.

Me gusta

Guardar

Me gusta

Guardar

Cite This Study

Bezin et al. (Thu,) studied this question.

synapsesocial.com/papers/69d95de05e5bcb4e3b835d20 https://doi.org/https://doi.org/10.2337/dc22-1148

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Biological actions and therapeutic potential of the glucagon-like peptides2002 · 500 citations
2Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation2010 · 645 citations
3A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions2002 · 1,321 citations
4Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies2011 · 932 citations
5Asymptotic Theory for Nested Case-Control Sampling in the Cox Regression Model1992 · 137 citations